Filing Flows › AIM ImmunoTech (AIM) › Q4 2024
AIM ImmunoTech (AIM) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
AIM ImmunoTech (AIM) reported revenue of $45K for the fourth quarter 2024 (Q4 2024), -31% from a year earlier and +29% from the quarter before.
AIM ImmunoTech, Q4 2024: revenue $45K (-31% year over year), net loss $6.0M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45K | +29% | -31% |
| Operating profit | −$5.9M | — | — |
| Net earnings | −$6.0M | — | — |
| Operating cash flow | −$4.0M | — | — |
What changed
Revenue was $45K in Q4 2024, down 31% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $5.9M, an operating margin of -13011.1%. Total costs fell 58% while revenue fell 31%. The quarter ended with a net loss of $6.0M, wider than the previous quarter's $3.7M loss.
Operating cash flow was −$4.0M. Non-cash charges added back $64K of depreciation and amortization and $196K of share-based compensation. Working capital and other items added $1.8M.
Questions
What was AIM ImmunoTech's revenue in the fourth quarter 2024?
AIM ImmunoTech (AIM) reported revenue of $45K for the fourth quarter 2024 (Q4 2024), -31% from a year earlier and +29% from the quarter before.
Source: AIM ImmunoTech 10-K on SEC EDGAR.